Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort ("PEMBROREAL" Study)

Alessandro Cafaro,Flavia Foca,Oriana Nanni,Marco Chiumente,Marina Coppola,Alberto Russi,Elena Svegliati,Paolo Baldo,Sabrina Orzetti,Fiorenza Enrico,Federico Foglio,Davide Pinnavaia,Vito Ladisa,Claudia Lauria Pantano,Rosa Lerose,Patrizia Nardulli,Simona Ferraiuolo,Piera Maiolino,Immacolata De Stasio,Federica Gradellini,Anna Rita Gasbarro,Rossella Santeramo,Gisella Carrucciu,Riccardo Provasi,Mario Cirino,Paola Cristina Cappelletto,Elisabetta Fonzi,Alessandra Pasqualini,Stefano Vecchia,Marianna Veraldi,Adele Emanuela De Francesco,Lucio Crinò,Angelo Delmonte,Carla Masini
DOI: https://doi.org/10.3390/cancers16101802
2024-05-09
Cancers
Abstract:Results from the phase III Keynote-024 clinical trial established pembrolizumab monotherapy as the first-line standard of care for patients with metastatic NSCLC who have PD-L1 expression ≥ 50%, EGFR, and ALK wild-type tumors. However, given the differences between patients treated in routine clinical practice and those treated in a clinical trial, real-world data are needed to confirm the treatment benefit in standard practice. Given the lack of data on large cohorts of patients with long follow-ups, we designed an observational retrospective study of patients with metastatic NSCLC who were treated with pembrolizumab, starting from its reimbursement eligibility until December 2020. The primary endpoints were PFS and OS, determined using the Kaplan–Meier method. Response and safety were also evaluated. We followed 880 patients (median follow-up: 35.1 months) until February 2022. Median PFS and OS were 8.6 months (95% CI: 7.6–10.0) and 25.5 months (95% CI: 21.8–31.6), respectively. We also found that ECOG PS, PD-L1 expression, and habitual smoking were prognostic factors for PFS, while age, sex, ECOG PS, habitual smoking and histology had an impact on OS. Multivariable analysis confirms the prognostic role of PD-L1 for PFS and of ECOG for both PFS and OS. 39.9% of patients reported an adverse event, but only 6.3% of patients discontinued therapy due to toxicity. Our results suggest a long-term benefit of pembrolizumab in the first-line setting, as well as a safety profile consistent with the results of Keynote-024. Many collected variables appear to influence clinical outcome, but results from these exploratory unadjusted analyses should be interpreted with caution.
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to evaluate the long - term efficacy and safety of using pembrolizumab as a first - line monotherapy in patients with metastatic non - small - cell lung cancer (NSCLC) with PD - L1 expression ≥50% in the real world. Specifically, the study aims to confirm whether the progression - free survival (PFS) and overall survival (OS) of pembrolizumab are consistent with the results in clinical trials in standard clinical practice, and to analyze the prognostic factors that affect these survival indicators. ### Research Background - **Clinical Needs**: Although pembrolizumab has shown significant efficacy in clinical trials, long - term data in actual clinical applications are still lacking. Especially for patients with metastatic NSCLC with PD - L1 expression ≥50%, more real - world data are needed to verify its efficacy and safety. - **Deficiencies in Existing Research**: Although there are some real - world studies, most of them have small sample sizes and short follow - up times, and cannot comprehensively reflect the performance of pembrolizumab in actual clinical practice. ### Research Objectives 1. **Primary Endpoints**: - **Progression - Free Survival (PFS)**: The time from the first use of pembrolizumab to disease progression or death. - **Overall Survival (OS)**: The time from the first use of pembrolizumab to death. 2. **Secondary Endpoints**: - **Objective Response Rate (ORR)**: The proportion of patients with complete or partial response. - **Disease Control Rate (DCR)**: The proportion of patients with complete or partial response or stable disease. - **Duration of Response (DoR)**: The time from the first recorded response to disease progression or death. - **Adverse Events (AEs)**: Any adverse reactions that occur during the treatment process. 3. **Prognostic Factor Analysis**: - Analyze the effects of factors such as age, gender, histological type, PD - L1 expression level, ECOG score, smoking history, and brain metastasis on PFS and OS. ### Research Methods - **Research Design**: Retrospective, multi - center study. - **Research Subjects**: 880 patients with metastatic NSCLC who received first - line pembrolizumab treatment in 16 centers in Italy from June 2017 to December 2020. - **Data Collection**: Extract patients' baseline characteristics, treatment conditions, follow - up results, and adverse events through medical records. - **Statistical Analysis**: Use the Kaplan - Meier method to calculate the median and 95% confidence interval of PFS and OS, and use the Cox regression model for multivariate analysis to evaluate independent prognostic factors. ### Research Significance - **Verify Clinical Trial Results**: Verify the long - term efficacy and safety of pembrolizumab in actual clinical applications through large - scale real - world data. - **Guide Clinical Practice**: Provide evidence on which patients may benefit more from pembrolizumab treatment, helping doctors to develop more personalized treatment plans. - **Policy - making**: Provide a scientific basis for the drug reimbursement policies of the national health system to ensure the effective use of resources. Through this study, researchers hope to fill the current gap in real - world data and provide more evidence support for the first - line treatment of patients with metastatic NSCLC.